About 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT)
MFAM Research
- [BUY] 4D Molecular Therapeutics (NASDAQ: FDMT) – One-Time Gene Therapy Heads Into a Defining Phase 3 Readout in Wet AMDOctober 16, 2026Buy rated by institutional sell-side research with a US$32.00 target, 148.6 per cent upside, ahead of Phase 3 wet AMD gene therapy data in 2Q27.
Our exclusive top 5 stock picks
Five high conviction stocks that didn't make the public list. Backed by institutional research. Subscribe for free access.
Thanks for subscribing, please check your email to confirm your subscription to instantly access your report.
Latest Announcements
No announcements yet.
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Biotechnology |
|---|---|